Introduction
============

Recent findings indicate a potential bi-directional relationship between psychiatric disorders and sleep disorders.[@b1-ndt-13-1193]--[@b3-ndt-13-1193] Obstructive sleep apnea (OSA), the most common type of sleep apnea, consists of repetitive episodes of upper airway obstruction occurring during sleep.[@b4-ndt-13-1193] Upper airway obstruction in OSA is attributed to excess soft tissue in the oropharynx, pharyngeal muscle dysfunction, or anatomical anomalies.[@b4-ndt-13-1193],[@b5-ndt-13-1193] Excessive body weight and an elevated body mass index (BMI) have been found to be major predisposing factors for OSA.[@b6-ndt-13-1193] The prevalence of OSA is well documented in the medical literature ranging from 5% in women to 7% in men.[@b7-ndt-13-1193] There is sparse data regarding the prevalence of OSA in our region (Middle East). In a study of Saudi patients with renal disease, the prevalence of OSA was \~20% compared to 5 to 7% among the general population.[@b8-ndt-13-1193],[@b9-ndt-13-1193] Sleep disturbances is a major diagnostic criterion in many mental health disorders. Research has shown an association between depressive symptoms and OSA.[@b10-ndt-13-1193] Depressive symptomatology has been documented in 21.5% of patients surveyed for sleep apnea.[@b11-ndt-13-1193] Additionally, a high prevalence of depressive symptoms was detected among individuals with a high likelihood of OSA.[@b12-ndt-13-1193],[@b13-ndt-13-1193] Little information concerning the relationship between psychiatric symptoms and sleep apnea exists in the Middle East region in general, and in Lebanon in particular (where this study was conducted).

Another symptom frequently reported in sleep disorders and psychiatric disorders is excessive daytime sleepiness (EDS). Psychiatric disorders have been found to account for 5 to 7% of EDS; with a higher prevalence in females.[@b14-ndt-13-1193] The prevalence of EDS in depression ranges from 5 to 50% depending on the definition of hyper-somnolence and how it is measured.[@b1-ndt-13-1193],[@b15-ndt-13-1193] EDS is commonly measured using the Epworth sleepiness scale (ESS).[@b16-ndt-13-1193] The normal range of daytime sleepiness was found, internationally, to correspond to an ESS score of less than 10.[@b17-ndt-13-1193]--[@b19-ndt-13-1193] A Middle Eastern study reported EDS prevalence at 20%, with a higher prevalence among women.[@b20-ndt-13-1193]

Most data regarding sleep disorders in psychiatric patients are usually collected from the general (outpatient) psychiatric population; among those with severe mental illness (hospitalized), little is known about the prevalence of sleep disorders. Individuals with severe mental illness are a high-risk group for poor health in general, with reduced access to preventative medical care for multiple reasons, including stigma and low socioeconomic status. Sleep-related complaints in this high-risk population are frequently dismissed as normal or as unavoidable consequences of psychotropic medications, lifestyle, or the mental illness itself. Identifying and treating sleep disorders in hospitalized psychiatric patients may improve outcomes, overall health, and quality of life in a vulnerable population.

The objective of this study was to portray a high prevalence of OSA and EDS among hospitalized psychiatric patients, higher than that of the general population as well as the general, non-hospitalized, psychiatric population. We attempted to investigate the risk of OSA, the prevalence of EDS, and associated variables in this population.

Methods
=======

The participants in this study were patients hospitalized at the acute psychiatric unit at the American University of Beirut Medical Center (AUB-MC) in Beirut, Lebanon. Following AUB-MC institutional review board approval, participant recruitment began. Over a period of 2 years all eligible patients admitted to the psychiatric unit were asked to participate. The research project, its risks, and benefits were explained to the participants before obtaining written informed consent from all of the participants. The study was a cross-sectional survey consisting of self-reported questionnaires and was administered by trained research assistants. Exclusion criteria included: being younger than 18 years of age, having a dementia diagnosis, and intellectual impairment that would prevent the individual from participating meaningfully in this study. Demographic and general medical information were included in the questionnaire; as well as alcohol and substance use including: caffeine, nicotine, and illicit drug use. The native language of the participants is Arabic and the questionnaires used in this study have been validated in Arabic speakers and Arab populations.

Psychiatric diagnoses upon admission to the psychiatric unit were also collected. The Berlin questionnaire was used to assess the risk of sleep apnea, and was used as a surrogate to test for sleep disordered breathing among the participants.[@b21-ndt-13-1193] The Berlin questionnaire is divided into three categories, patients with positive scores in at least two of these categories are considered to have a high risk of sleep apnea. The first category addresses the presence and intensity of snoring, the second category addresses sleep-related fatigue, and the third category addresses the presence or absence of elevated blood pressure.[@b21-ndt-13-1193] The Berlin questionnaire has been validated in Arabic speaking populations.[@b22-ndt-13-1193]

The ESS was used to evaluate EDS.[@b16-ndt-13-1193] It consists of eight items describing different situations in which the individual would have a likelihood of dozing off. Each item is scored from 0 to 3, with 3 being the highest chance of dozing off. A score greater than 10 suggests abnormal daytime sleepiness.[@b16-ndt-13-1193] The ESS has been validated in Arabic speakers.[@b23-ndt-13-1193]

The patient health questionnaire 9 (PHQ-9) was used to evaluate depressive symptoms.[@b24-ndt-13-1193] It includes nine items; for each item participants indicate if the described symptom had bothered them "not at all", "several days", "more than half the days", or "nearly every day" over the past 2 weeks. Scores per item range from 0 to 3. Scores in the following ranges: 10 to 14; 15 to 19; and 20 or more correspond to moderate, moderately severe, and severe depressive symptoms, respectively. The PHQ-9 has a sensitivity of 93% and a specificity of 88% when used to evaluate depressive symptomatology.[@b24-ndt-13-1193] The generalized anxiety disorder 7 (GAD-7) survey,[@b25-ndt-13-1193] a 7-item scale, is a screening tool for anxiety.[@b25-ndt-13-1193] For each item, participants indicate whether, during the past 2 weeks, an anxiety symptom bothered them: "not at all", "several days", "more than half the days", or "nearly every day". Scores of 5, 10, and 15 are taken as the cutoff points for mild, moderate, and severe anxiety. The GAD-7 has a sensitivity of 89% and a specificity of 82% for detecting anxiety symptoms.[@b25-ndt-13-1193] The GAD-7 and PHQ-9 have both been validated in Arabic speaking populations.[@b26-ndt-13-1193]

Collected data were recorded in an electronic database and analyzed using SPSS^®^ (IBM Corporation, Armonk, NY, USA) for Windows^®^ version 20. The prevalence of OSA, as well as the descriptive analyses for all variables were presented as number and percent. Associations between potential factors and patient characteristics relevant to OSA were assessed using the Pearson Chi square test. Multivariate analyses were performed to determine possible predictors of OSA and EDS. All tests were 2-sided with a type one error of 0.05.

Results
=======

The investigators recruited 152 participants from the patients hospitalized at the AUB-MC psychiatric unit. Our psychiatric unit admits \~250 patients per year. The sample used in this study was collected over 2 years. Some of the patients admitted to the unit did not agree to participate, and some did not meet criteria for inclusion. We estimate a response rate of \~30%. The participants were 56.6% female and the average age range was 26 to 45. The demographic and descriptive characteristics of the group are shown in [Table 1](#t1-ndt-13-1193){ref-type="table"}. As expected, a lower risk of sleep apnea, per the Berlin questionnaire scores, was detected in females when compared to males ([Table 1](#t1-ndt-13-1193){ref-type="table"}). Most of the participants were overweight, and this group had the highest risk of sleep apnea. The primary psychiatric diagnoses of the participants upon admission to the psychiatric unit are listed in [Table 1](#t1-ndt-13-1193){ref-type="table"}. Depression was the most common admitting diagnosis at 44.0% ([Table 1](#t1-ndt-13-1193){ref-type="table"}). When the participants were asked if they ever received a diagnosis of sleep apnea, or ever used continuous positive airway pressure or bi-level positive airway pressure devices for treatment of OSA, only 5% responded affirmatively. Per the Berlin questionnaire, 39.5% of the participants were found to have a high risk of sleep apnea. OSA was found to be associated with BMI (*P*=0.02) and PHQ-9 scores (*P*=0.01). As expected, higher BMIs were associated with a higher risk of sleep apnea (*P*=0.02) ([Table 1](#t1-ndt-13-1193){ref-type="table"}). Severity of depressive symptoms was also associated with a higher risk of sleep apnea (*P*=0.01) ([Table 1](#t1-ndt-13-1193){ref-type="table"}). The psychiatric diagnoses of the participants and anxiety symptoms (per GAD-7) were not found to have a significant association with the risk of sleep apnea ([Table 1](#t1-ndt-13-1193){ref-type="table"}).

After administering the ESS, only 9.9% of the participants were found to have abnormal daytime sleepiness ([Table 2](#t2-ndt-13-1193){ref-type="table"}). Out of 152 patients, 77.6% slept for less than 7 to 8 hours at night and out of those patients, 46.7% had an abnormal range of daytime sleepiness ([Table 2](#t2-ndt-13-1193){ref-type="table"}). Multivariate analyses were done which showed an age range of 18--25 years old, male sex, BMI, and depressive symptoms to be significant predictors of OSA ([Table 3](#t3-ndt-13-1193){ref-type="table"}). The only significant predictor of EDS in this sample was found to be the age range 18--25 years old ([Table 4](#t4-ndt-13-1193){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this study is the first to assess OSA and EDS among psychiatric patients in the Middle East. The results of this study show a high risk of OSA among hospitalized psychiatric patients. The risk of sleep apnea found in this study (39.5%) was higher than the prevalence rates of OSA among the general population. Prevalence rates generally range from 5% in women to 7% in men,[@b7-ndt-13-1193] with prevalence increasing in women as they age.[@b27-ndt-13-1193] The prevalence of sleep apnea in this sample was found to be higher in males, which is consistent with the literature ([Table 1](#t1-ndt-13-1193){ref-type="table"}). The prevalence of sleep apnea was not found to be higher in older patients, which is unusual per the literature. Being in the younger age range was found to be a predictor of OSA ([Table 3](#t3-ndt-13-1193){ref-type="table"}). Despite having a low odds ratio (OR), this finding was still significant. This underscores the importance of not overlooking OSA symptoms and their risks in the young psychiatric patient population. This could also be explained by the small sample size when compared to larger general population studies. The prevalence of OSA in this study, was found to be higher than available prevalence data from our region regarding OSA which showed a prevalence ranging up to 21% in special populations, such as end-stage renal failure patients.[@b8-ndt-13-1193],[@b9-ndt-13-1193],[@b28-ndt-13-1193] The high prevalence in this study, may be due to factors related to the severity of psychiatric disorders in our sample that can exacerbate sleep apnea; such as the effects of sedating psychotropic medications on breathing during sleep, and the increased prevalence of metabolic syndrome, obesity, drug and alcohol use in this population.[@b29-ndt-13-1193]

Obesity is a major predictive factor for sleep apnea,[@b6-ndt-13-1193],[@b8-ndt-13-1193] the results of our study are consistent with the literature, with 25.0% of OSA patients in our sample being obese, and 45.0% overweight ([Table 1](#t1-ndt-13-1193){ref-type="table"}). Psychiatric disorders have been shown to contribute to the development and maintenance of sleep apnea.[@b29-ndt-13-1193],[@b30-ndt-13-1193] Sleep apnea is associated with fatigue and negatively affects quality of life.[@b31-ndt-13-1193],[@b32-ndt-13-1193] Concomitant depression or anxiety worsens the quality of life in patients with sleep apnea, and patients frequently end up in a vicious cycle of worsening sleep and psychiatric symptoms.[@b3-ndt-13-1193] The prevalence of OSA in the depressed population is known to be higher than the general population;[@b33-ndt-13-1193] the results of our study show that 75.0% of patients with a high risk of sleep apnea have severe depressive symptoms ([Table 1](#t1-ndt-13-1193){ref-type="table"}). Sedating psychiatric medications and specifically benzodiazepines, might be a major contributor to the co-existence of sleep apnea in more depressed patients. Benzodiazepines decrease the respiratory effort and directly exacerbate OSA.[@b34-ndt-13-1193]

Even though the role of serotonin in depression is well established, its contribution to sleep apnea is still questionable.[@b35-ndt-13-1193] The bi-directional relationship between depression and OSA may have underlying biological links. Inflammatory markers such as TNF-alpha, C-reactive protein (CRP), and IL-6 have been shown to be elevated in OSA patients and similarly in depression, and they may link depression and OSA.[@b36-ndt-13-1193],[@b37-ndt-13-1193] Specific inflammatory cytokines have also been linked to obesity, depression, and OSA.[@b38-ndt-13-1193] The persistent elevation of these inflammatory markers in individuals who have both disorders might perpetuate refractory psychiatric symptoms.

The prevalence of EDS in this sample was approximately 10%, which is consistent with reported hypersomnia in psychiatric disorders; albeit in the lower range.[@b1-ndt-13-1193],[@b15-ndt-13-1193] Abnormal daytime sleepiness in this sample was not found to be associated with any of the tested variables ([Table 2](#t2-ndt-13-1193){ref-type="table"}). This was an unusual finding considering that EDS has been shown to be associated with some psychiatric disorders and psychotropic medications.[@b14-ndt-13-1193],[@b39-ndt-13-1193] This finding could be attributed to under-reporting by our participants of their EDS. Despite most patients in this study sleeping less than 7 to 8 hours per day, there was no significant association between reported sleep time and EDS. A possible explanation for this finding may be habituation to chronic EDS in this patient population. Objective measures of EDS, such as polysomnography with mean sleep latency testing, would be able to further quantify daytime sleepiness in this patient population. The relatively lower prevalence of EDS could also potentially be attributed to positive behavioral changes, and improved sleep hygiene that the participants are exposed to during their stay at the psychiatric unit. Switching or adjusting the patients' psychotropic medications during hospitalization might also have contributed to the lower prevalence of EDS in this sample. In a previous study, patients with substance abuse were found to be at a very high risk of experiencing sleep disorders.[@b40-ndt-13-1193] Even though EDS in this sample was not found to be associated with drug abuse, the percentage of patients who reported illicit drug use in this sample was low. Overall, EDS in psychiatric patients is very challenging to evaluate and treat. In some cases of severe hypersomnia, the culprit was found to be narcolepsy, and due to overlap in symptoms some patients were misdiagnosed as schizophrenics, and the treatment of the narcolepsy-related hypersomnia was overlooked or delayed.[@b41-ndt-13-1193]

OSA was found to be associated with depressive symptomatology in general, but there was no significant association with specific psychiatric diagnoses in our sample. This could be attributed to the relatively small sample size. Another limitation to this study, is not taking into account the specific types of psychotropic medications being administered to the patients and their potential effects on sleep. Data on prescribed medications were collected; however, to be able to obtain statistically meaningful results from analyzing the effects of medications in our population, an unfeasibly large sample size would be required given the heterogeneity of medications prescribed for the multiple psychiatric disorders. This was a questionnaire-based study, which by itself is a significant limitation, incorporating objective measures such as actigraphy and polysomnography in a future study will provide more robust data. This study may have under-reported sleep disordered breathing in general, by not detecting other types of apnea, mainly central sleep apnea. Central sleep apnea may be quite prevalent in this population since many participants are prescribed centrally acting depressants.

Sleep disorders in general and sleep disordered breathing in particular among psychiatric patients, are frequently overlooked or underestimated. In a recent study by our group, restless legs syndrome was found to be highly prevalent among hospitalized psychiatric patients at 18%, and was associated with suicidal ideation.[@b42-ndt-13-1193]

Conclusion
==========

Among the patients who were found to have a high risk of sleep apnea in this study, only a minimal percentage of them received a previous diagnosis of sleep apnea or were currently being treated for sleep apnea; this finding underscores the need to increase screening for sleep disorders in this vulnerable population. It is also important to address OSA in this population; since OSA is associated with increased cardiovascular morbidity, and will increase morbidity in psychiatric patients who are already at a higher risk of increased metabolic and cardiovascular diseases. The biological factors underlying the relationship between sleep and psychiatric disorders are multifactorial and complex, however it is important to improve screening and offer appropriate therapeutic intervention to improve outcomes and quality of life in psychiatric patients.
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###### 

Patients' characteristics and risk of sleep apnea per the Berlin questionnaire

                                            Patients with high risk of sleep apnea, n (%) N=60   Patients with low risk of sleep apnea, n (%) N=92   *P*-value
  ----------------------------------------- ---------------------------------------------------- --------------------------------------------------- -----------
  Sex                                                                                                                                                0.16
   Male                                     30 (50.0)                                            35 (38.5)                                           
   Female                                   30 (50.0)                                            56 (61.5)                                           
  Age (years)                                                                                                                                        0.06
   18--25                                   9 (15.0)                                             33 (35.9)                                           
   26--35                                   18 (30.0)                                            25 (27.2)                                           
   36--45                                   18 (30.0)                                            18 (19.6)                                           
   46--55                                   8 (13.3)                                             10 (10.9)                                           
   \>55                                     7 (11.7)                                             6 (6.5)                                             
  BMI categories                                                                                                                                     0.02
   Underweight                              2 (3.3)                                              8 (8.9)                                             
   Normal                                   16 (26.7)                                            40 (44.4)                                           
   Overweight                               27 (45.0)                                            37 (41.1)                                           
   Obese                                    15 (25.0)                                            5 (5.6)                                             
  Diagnosis                                                                                                                                          0.33
   Depression                               31 (51.7)                                            36 (39.1)                                           
   Schizophrenia/schizoaffective disorder   10 (16.7)                                            11 (12.0)                                           
   Bipolar                                  5 (8.3)                                              19 (20.7)                                           
   Anxiety disorder                         6 (10.0)                                             10 (9.8)                                            
   SUD                                      8 (13.3)                                             15 (16.3)                                           
   Eating disorder                          0 (0.0)                                              1 (1.1)                                             
  Depressive symptoms                                                                                                                                0.01
   None                                     5 (8.3)                                              18 (19.6)                                           
   Mild to moderate                         10 (16.7)                                            26 (28.3)                                           
   Severe                                   45 (75.0)                                            48 (52.2)                                           
  Anxiety symptoms                                                                                                                                   0.47
   No anxiety                               10 (35.7)                                            18 (19.6)                                           
   Mild                                     19 (31.7)                                            25 (27.2)                                           
   Moderate                                 5 (37.5)                                             15 (16.3)                                           
   Severe                                   26 (43.3)                                            34 (37.0)                                           
  Tobacco                                   42 (70.0)                                            54 (58.7)                                           0.16
  Caffeine                                  49 (81.7)                                            77 (83.7)                                           0.74
  Alcohol                                   19 (31.7)                                            31 (33.7)                                           0.79
  Substance abuse                                                                                                                                    0.37
   Cannabis                                 6 (10.0)                                             17 (18.5)                                           
   Cocaine                                  1 (1.7)                                              0 (0.0)                                             
   Non-prescribed opiates                   1 (1.7)                                              1 (1.1)                                             
   Non-prescribed benzodiazepines           4 (6.7)                                              3 (3.3)                                             

**Abbreviations:** BMI, body mass index; SUD, substance use disorder.

###### 

Patients' characteristics and range of daytime sleepiness as per Epworth sleepiness scale

                                            Patients with normal range of sleepiness, n (%)N=137   Patients with abnormal range of sleepiness, n (%) N=15   *P*-value
  ----------------------------------------- ------------------------------------------------------ -------------------------------------------------------- -----------
  Sex                                                                                                                                                       0.18
   Male                                     61 (44.9)                                              4 (26.7)                                                 
   Female                                   75 (55.1)                                              11 (73.3)                                                
  Age (years)                                                                                                                                               0.29
   18--25                                   35 (25.5)                                              7 (46.7)                                                 
   26--35                                   41 (29.9)                                              2 (13.3)                                                 
   36--45                                   32 (23.4)                                              4 (26.7)                                                 
   46--55                                   16 (11.7)                                              2 (13.3)                                                 
   \>55                                     13 (9.5)                                               0 (0.0)                                                  
  BMI categories                                                                                                                                            0.77
   Underweight                              9 (6.7)                                                1 (6.7)                                                  
   Normal                                   52 (38.5)                                              4 (26.7)                                                 
   Overweight                               57 (42.2)                                              7 (46.7)                                                 
   Obese                                    17 (12.6)                                              3 (20.0)                                                 
  Sleep hours                                                                                                                                               0.91
   Less than 7 to 8 hours                   69 (50.4)                                              7 (46.7)                                                 
   More than 8 hours                        68 (49.6)                                              8 (54.3)                                                 
  Diagnosis                                                                                                                                                 0.90
   Depression                               62 (45.3)                                              5 (33.3)                                                 
   Schizophrenia/schizoaffective disorder   19 (13.9)                                              2 (13.3)                                                 
   Bipolar                                  20 (14.6)                                              4 (26.7)                                                 
   Anxiety disorder                         13 (9.5)                                               2 (13.3)                                                 
   Substance use disorder                   21 (15.3)                                              2 (13.3)                                                 
   Eating disorder                          1 (0.7)                                                0 (0.0)                                                  
  Depressive symptoms                                                                                                                                       0.53
   None                                     22 (95.7)                                              1 (4.3)                                                  
   Mild to moderate                         33 (91.7)                                              3 (8.3)                                                  
   Severe                                   82 (88.2)                                              11 (11.8)                                                
  Anxiety symptoms                                                                                                                                          0.84
   No anxiety                               26 (92.9)                                              2 (7.1)                                                  
   Mild                                     40 (90.9)                                              4 (9.1)                                                  
   Moderate                                 17 (85.0)                                              3 (15.0)                                                 
   Severe                                   54 (90.0)                                              6 (10.0)                                                 
  Tobacco                                   86 (62.8)                                              10 (66.7)                                                0.76
  Caffeine                                  113 (82.5)                                             13 (86.7)                                                0.68
  Alcohol                                   45 (32.8)                                              5 (33.3)                                                 0.97
  Substance abuse                                                                                                                                           0.84
   Cannabis                                 22 (16.1)                                              1 (6.7)                                                  
   Cocaine                                  1 (0.7)                                                0 (0.0)                                                  
   Non-prescribed opiates                   2 (1.5)                                                0 (0.0)                                                  
   Non-prescribed benzodiazepines           6 (4.4)                                                1 (6.7)                                                  

**Abbreviation:** BMI, body mass index.

###### 

Multivariate analysis of potential predictors of sleep apnea

                        Obstructive sleep apnea (reference: low)   
  --------------------- ------------------------------------------ -------
  Age 18--25 years      0.29 (0.12--0.71)                          0.01
  Sex                   2.06 (0.98--4.34)                          0.06
  BMI -- obese          5.97 (1.89--18.82)                         0.002
  Depressive symptoms   4.04 (1.80--9.07)                          0.001

**Notes:** Variables included in the model were: age (reference: 26--35 years), sex (reference: female); BMI (reference: normal); depressive symptoms (reference: none); anxiety (reference: none); tobacco (reference: none); caffeine (reference: none); alcohol (reference: none).

**Abbreviations:** BMI, body mass index; OR, odds ratio; CI, confidence interval.

###### 

Multivariate analysis of potential predictors of excessive daytime sleepiness

                     Range of sleepiness (reference: normal)   
  ------------------ ----------------------------------------- ------
  Age 18--25 years   2.55 (0.86--7.54)                         0.09

**Notes:** Variables included in the model were: age (reference: 26--35 years), sex (reference: female); BMI (reference: normal); depressive symptoms (reference: none); anxiety (reference: none); tobacco (reference: none); caffeine (reference: none); alcohol (reference: none).

**Abbreviations:** BMI, body mass index; OR, odds ratio; CI, confidence interval.
